The goal of this study is to analyze the impact of innovation on entry, that is, the launch of a new product, for some specific three digit cardiovascular sector in the US pharmaceutical market, for the period 1988-1998. We have a panel data obtained by crossing-check IMS Health Data on sales with data on patents for companies selling products into those submarkets. We estimate a logit panel model by controlling for endogeneity, adopting submarket and firm specific variables. Our results show that own patents don’t clearly encourage entry, while patent holdings by incumbents have contrasting effects: on one hand the initial stock act as a barrier to entry, on the other hand they promote entry through the opening of new technological opportunities.
Entry and Patents: Evidence from the US Cardiovascular Pharmaceutical Sector / DI IORIO, Francesca; Giorgetti, M. L.. - Department of Economics, Management and Quantitative Methods at Università degli Studi di Milano Departmental Working Papers:(2017).
Entry and Patents: Evidence from the US Cardiovascular Pharmaceutical Sector
DI IORIO, FRANCESCA;
2017
Abstract
The goal of this study is to analyze the impact of innovation on entry, that is, the launch of a new product, for some specific three digit cardiovascular sector in the US pharmaceutical market, for the period 1988-1998. We have a panel data obtained by crossing-check IMS Health Data on sales with data on patents for companies selling products into those submarkets. We estimate a logit panel model by controlling for endogeneity, adopting submarket and firm specific variables. Our results show that own patents don’t clearly encourage entry, while patent holdings by incumbents have contrasting effects: on one hand the initial stock act as a barrier to entry, on the other hand they promote entry through the opening of new technological opportunities.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
